Premaitha Health PLC Directorate change (7612C)
October 03 2018 - 2:00AM
UK Regulatory
TIDMNIPT
RNS Number : 7612C
Premaitha Health PLC
03 October 2018
Premaitha Health PLC
("Premaitha" or the "Company")
Directorate change
Premaitha Health PLC (AIM: NIPT), a leading international
molecular diagnostics group focused on non-invasive prenatal
testing ("NIPT"), announces that, further to the announcement made
by the Company on 20 September 2018, Mr Hayden Jeffreys has been
appointed as Group Commercial Director to the Company following
completion of customary director due diligence. Mr Jeffreys will
take up his position on the Board of Premaitha with immediate
effect.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies, the following information is disclosed in respect of Mr
Hayden William Jeffreys (aged 42):
Current Appointments Appointments in the last
5 years
Cambridge DX Limited Delta Biologicals Srl
Diamedix Inc
Drew Scientific Inc
Erba Diagnostics Inc
Erba Diagnostics Mexico S.A.
Erba Mannheim Gmbh
Immunovision Inc
Jas Diagnostics Inc
Lumora Limited
There is no further information regarding Mr Jeffreys required
to be disclosed under the AIM Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
Enquiries
Premaitha Health plc Tel: +44 (0) 161
667 6865
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0) 20
7213 0880
Liam Murray / James Caithie
finnCap (Broker) Tel: +44 (0) 20
7220 0500
Geoff Nash / Matthew Radley (Corporate Finance)
Tim Redfern (Corporate Broking)
Vigo Communications Tel: +44 (0) 20
7390 0234
Ben Simons / Fiona Henson / Antonia Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is an international molecular diagnostics group which
uses the latest advances in DNA analysis technology to develop
safer, faster and regulatory approved genetic screening tests. The
Group's primary focus is on non-invasive prenatal tests (NIPT) for
pregnant women - an emerging, multi-billion dollar global
market.
Premaitha's IONA(R) test was launched in 2015 as the first
CE-IVD NIPT test in Europe. It enables laboratories and healthcare
practitioners to offer a complete CE-marked NIPT system in-house.
The IONA(R) test is performed on a maternal blood sample - which
contains traces of placental DNA - and estimates the risk of a
fetus being affected with Down's syndrome or other genetic
conditions.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary invasive follow up
diagnostic procedures, such as amniocentesis, which are costly,
resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a
specialist next generation sequencing and bioinformatics company
based in Taiwan, with its own NIPT screening test that operates on
the same Thermo Fisher next-generation sequencing platform as
Premaitha's IONA(R) test. Yourgene brings significant benefits to
the Group through expanded market access in Asia - the world's
fastest growing NIPT market - as well as opportunities for
cross-selling and the ability to jointly develop expanded test
content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene
offices in Taipei and Singapore. Its shares trade on the AIM market
of the London Stock Exchange (AIM: NIPT). For further information,
please visit www.premaitha.com. Follow us on twitter
@PremaithaHealth.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUGGAAUUPRGQP
(END) Dow Jones Newswires
October 03, 2018 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024